Granted Patent B2

US 12,509,469 · App. 17/633,072 · Granted Dec 30, 2025

Inventors: Ian Charles Parrag (Toronto, CA); Wendy Alison Naimark (Toronto, CA); Matthew Alexander John Statham (Milton, CA); Georgios Rizis (Toronto, CA); Kyle Giovanni Battiston (Toronto, CA)

Assignee: Ripple Therapeutics Corporation

C07D489/02A61K9/0024A61K47/542A61K47/545A61K47/55A61K47/552C07D489/08

Abstract

Claims (25)

1 . A compound having a structure represented by Formula (IID):

wherein:

R 1 and R 1 ′ are each independently unsaturated alkyl; or R 1 and R 1 ′ are each independently cycloalkyl;

R a and R a ′ are each independently H or —OH;

L d is selected from the group consisting of —(CR 2 ) y —, —O(CR 2 ) y O—, —O(CR 2 ) y —, —(CR 2 ) y O—, and —O(CH 2 CH 2 O) y —, wherein y is 1-10 and each R is independently selected from the group consisting of H, hydroxyl, halogen, alkyl, or is taken together with another R to form an optionally substituted cycloalkyl; and

X and X′ are each independently O or CH 2 , or

a pharmaceutically salt thereof.

2 . A compound having a structure represented by:

3 . The compound of claim 1 , wherein R 1 and R 1 ′ are each independently unsaturated alkyl.

4 . The compound of claim 1 , wherein R 1 and R 1 ′ are each independently cycloalkyl.

5 . The compound of claim 1 , wherein R a and R a ′ are each H.

6 . The compound of claim 1 , wherein R a and R a ′ are each —OH.

7 . The compound of claim 1 , wherein X and X′ are each O.

8 . The compound of claim 1 , wherein X and X′ are each CH 2 .

9 . The compound of claim 1 , wherein L d is —(CR 2 ) y — or —O(CR 2 ) y O—, wherein y is 1-10 and each R is independently selected from the group consisting of H, hydroxyl, halogen, alkyl, or is taken together with another R to form an optionally substituted cycloalkyl.

10 . A pharmaceutical implant or article comprising a compound having a structure represented by Formula (IID):

wherein:

R 1 and R 1 ′ are each independently unsaturated alkyl or cycloalkyl;

R a and R a ′ are each independently H or —OH;

L d is selected from the group consisting of —(CR 2 ) y —, —O(CR 2 ) y O—, —O(CR 2 ) y —, —(CR 2 ) y O—, and —O(CH 2 CH 2 O) y —, wherein y is 1-10 and each R is independently selected from the group consisting of H, hydroxyl, halogen, alkyl, or is taken together with another R to form an optionally substituted cycloalkyl; and

X and X′ are each independently O or CH 2 , or

a pharmaceutically salt thereof.

11 . The pharmaceutical implant or article of claim 10 , wherein the implant or article comprises at least 50 wt. % of the compound and/or pharmaceutically acceptable salt thereof.

12 . A pharmaceutical implant or article comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

13 . The pharmaceutical implant or article of claim 12 , wherein the implant or article comprises at least 50 wt. % of the compound and/or pharmaceutically acceptable salt thereof.

Assignments (1)

Continuity (3)

References Cited (247)